Alliance to present at the UK Investor Show

RNS Number : 7753K

Alliance Pharma PLC

13 April 2018

 

For immediate release

13 April 2018

RNS REACH

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Alliance to present at the UK Investor Show 

Alliance Pharma PLC (AIM: APH) the specialty pharmaceutical company, is delighted to announce that it will be presenting at the UK Investor Show, Britain's largest one day investor event.

The event will take place on Saturday 21 April 2018 at the Queen Elizabeth II Conference Centre in Westminster, London.

John Dawson, CEO of Alliance Pharma, will be presenting at 11.20am and taking questions. Peter Butterfield, Deputy CEO, and Andrew Franklin, CFO, will also be available from 8.30am until 5.30pm at stand 49 to discuss the Company's recent progress as well as its growth strategy.

For more details on the event please visit: www.ukinvestorshow.com

For further information:

Alliance Pharma plc                                                                                 + 44 (0) 1249 466966

John Dawson, Chief Executive Officer

Peter Butterfield, Deputy Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

Buchanan                                                                                                  + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Gemma Mostyn-Owen

Numis Securities Limited                                                                        + 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black / Toby Adcock

Investec Bank plc                                                                                      [phone]

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Rob Baker

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

NRAFKBDNQBKDKQD